RT Journal Article
SR Electronic
T1 Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP P373
DO 10.1186/2051-1426-3-S2-P373
VO 3
IS Suppl 2
A1 Srivastava, Minu
A1 Murriel, Christopher
A1 Yun, Rui
A1 Mayes, Erin
A1 Jie, Hyun-Bae
A1 Axelrod, Fumiko
A1 Xie, Ming-Hong
A1 Bentley, Trevor
A1 Cancilla, Belinda
A1 Tam, Raymond
A1 O'Young, Gilbert
A1 Kapoun, Ann
A1 Lewicki, John
A1 Hoey, Tim
A1 Gurney, Austin
A1 Inkyung, Park Angie
YR 2015
UL http://jitc.bmj.com/content/3/Suppl_2/P373.abstract